公开(公告)号：US10196447B2

公开(公告)日：2019-02-05

申请号：US15563950

申请日：2016-04-12

Applicant: Academia Sinica

Inventor： Han-Chung Wu ,  Ruei-Min Lu ,  Chiung-Yi Chiu ,  I-Ju Liu ,  Yu-Ling Chang

IPC: A61K39/00 ,  A61P35/00 ,  A61P35/02 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  A61K31/337 ,  A61K39/395 ,  C12N15/113 ,  G01N33/574

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：US10195231B2

公开(公告)日：2019-02-05

申请号：US15109537

申请日：2014-12-23

Applicant: Academia Sinica

Inventor： Nan-Shih Liao ,  Jan-Mou Lee

IPC: A61K35/17 ,  C12N5/0783 ,  A61K38/20 ,  A61K38/21

Abstract: Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.

公开(公告)号：US20190030120A1

公开(公告)日：2019-01-31

申请号：US15660116

申请日：2017-07-26

Applicant: ACADEMIA SINICA

Inventor： Ming-Daw TSAI ,  Tong-You Wade WEI ,  Pei-Yu WU

IPC: A61K38/17 ,  C07K14/47 ,  A61K45/06 ,  C12N15/113

Abstract: The present invention relates to use of TRAF-interacting protein with an FHA domain (TIFA) antagonists for treating diseases. Particularly, the present invention relates to an isolated peptide fragment from TIFA which acts as a dominant negative inhibitor of TIFA and is effective in treating cancer or an inflammatory disorder. The present invention also relates to a method for predicting cancer prognosis based on the TIFA expression level in a subject in need. The present invention further relates to a method for treating a disease via TIFA silencing.

公开(公告)号：US20190022245A1

公开(公告)日：2019-01-24

申请号：US16111242

申请日：2018-08-24

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： STEVEN R ROFFLER ,  TIAN-LU CHENG ,  CHIEN-HAN KAO ,  BING-MAE CHEN ,  YU-CHENG SU ,  HSIN-YI TUNG ,  Kuo-Hsiang Chuang

IPC: A61K47/68 ,  C07K16/32 ,  A61K49/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US10150818B2

公开(公告)日：2018-12-11

申请号：US14798312

申请日：2015-07-13

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Tsui-Ling Hsu ,  Yi-Wei Lou ,  Chih-Wei Lin ,  Shih-Chi Yeh ,  Chung-Yi Wu ,  Han-Chung Wu

IPC: C07K16/44 ,  G01N33/574 ,  C07K16/30 ,  C07K16/18 ,  A61K39/00

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：US20180346896A1

公开(公告)日：2018-12-06

申请号：US15750753

申请日：2016-08-05

Applicant: Academia Sinica

Inventor： Steve Roffler ,  Huai-Yao Chuang

IPC: C12N9/24 ,  C12Q1/40

CPC classification number: C12N9/24 ,  A61K38/00 ,  C12Y302/01031 ,  C12Y302/01076

Abstract: An engineered enzyme, comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of a human beta-glucuronidase, wherein the engineered enzyme exhibits a higher level of alpha-iduronidase enzymatic activity as compared to the human beta-glucuronidase.

公开(公告)号：US20180320192A1

公开(公告)日：2018-11-08

申请号：US15923288

申请日：2018-03-16

Applicant: Academia Sinica

Inventor： Tuan-Hua HO ,  I-Chieh TSENG ,  Su-May YU ,  Shuen-Fang LO

IPC: C12N15/82

CPC classification number: C12N15/8271 ,  C12N15/8273

Abstract: The present invention relates to a method of improving stress tolerance and/or preventing growth reduction of a plant by introducing a polynucleotide encoding a Repetitive Proline-rich Protein (RePRP) into the plant.

公开(公告)号：US10112198B2

公开(公告)日：2018-10-30

申请号：US14836390

申请日：2015-08-26

Applicant: Academia Sinica

Inventor： Ying-Chih Chang ,  Jr-Ming Lai ,  Jen-Chia Wu

IPC: B81B1/00 ,  B01L3/00 ,  B01F5/00

Abstract: The disclosure provides for compositions and methods for the collection of rare cells using an interspersed microstructure design.

公开(公告)号：US10111951B2

公开(公告)日：2018-10-30

申请号：US15689165

申请日：2017-08-29

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Alice L. Yu ,  Kun-Hsien Lin ,  Tai-Na Wu

IPC: A61K39/39 ,  C07H15/18 ,  A61K39/00

Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

公开(公告)号：US20180264129A1

公开(公告)日：2018-09-20

申请号：US15987889

申请日：2018-05-23

Applicant: Academia Sinica

Inventor： Tse-Wen CHANG ,  Hsing-Mao CHU ,  Chun-Yu LIN

IPC: A61K47/68 ,  C07K16/24 ,  A61K47/61 ,  A61K47/64 ,  A61K47/60 ,  A61K31/397 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/537 ,  A61K31/739 ,  A61K51/06 ,  C07K16/46 ,  C07K16/32 ,  C07K16/28 ,  A61K47/58 ,  C07K16/22 ,  C07K16/18 ,  C07K14/715 ,  C07K14/705 ,  C07K14/655 ,  C07K14/485 ,  A61K51/08 ,  A61K39/00

CPC classification number: A61K47/6803 ,  A61K31/397 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/537 ,  A61K31/739 ,  A61K47/58 ,  A61K47/60 ,  A61K47/61 ,  A61K47/64 ,  A61K47/6801 ,  A61K47/6843 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6883 ,  A61K51/065 ,  A61K51/088 ,  A61K2039/505 ,  C07K14/485 ,  C07K14/655 ,  C07K14/705 ,  C07K14/70578 ,  C07K14/7151 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2875 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33

Abstract: The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element via the click chemistry.